why we started arcstone
For every great health innovation, there comes a day when the local market is no longer enough.
You built something that works. Your science is proven, and your local customers love it. But to truly change the world – and to find the scale your innovation deserves – you have to look toward the United States.
For most mid-sized companies, the U.S. feels like a "black box."
You told us that you have the vision to lead but are held back by three core fears
The price tag
You fear unpredictable costs that drain their capital before they even launch.
The complexity
You fear a process so complex that they get lost in the FDA, legal, and insurance systems.
The empty handshake
You fear transactional vendors who take money, deliver a report, and leave you to struggle alone.
Time to meet us
Julien Willard breaks down the Arcstone in 60 seconds. Who we are. What we do. How we bring our intellectual power and modern technologies to help you succeed.
We built Arcstone to be that partner you looked for
We believe that no breakthrough should stay small because of a border. We moved away from the "consulting" model because advice doesn't solve these fears. Operations do.
Arcstone is the operator that stays. We replace unpredictable costs with clear, milestone-based growth. We replace the maze with a proven operational platform. Most importantly, we replace the transactional vendor with an embedded U.S. team that has your back.
No hidden fees or "consulting hours." We build a budget for results, not for meetings.
We own the process from the FDA to the first customer, so you always know where you stand.
We don't work for you. We work with you, inside your business, as your U.S. operational spine.
Your leadership team
Business strategy and trade team with extensive access to fractional executive bench
Willard is a physician and health economist who spent two decades advising life sciences companies on growth strategy, market entry, and M&A. He has guided portfolio transformations exceeding $20 billion, led restructurings delivering $1 billion in operational savings, and structured cross-border transactions ranging from $500 million to $10 billion.
He was Partner and Head of Life Sciences Strategy at IBM Consulting and held senior roles at Accenture, PwC, and the World Bank.
Willard's background is unusual: clinical training as a physician, graduate work in health economics at the London School of Hygiene and Tropical Medicine, and early career postings as a diplomat and foreign service officer across four continents. That combination – clinical fluency, economic rigor, and negotiation discipline – shapes how he approaches market entry.
Ursuy is a global business strategist with over twelve years of experience advising companies on international expansion, market entry, and cross-border operations. He has led go-to-market strategies for companies ranging from $15 million to $80 million in revenue, delivered margin improvements of 10-20% through market repositioning, and identified over €23 million in untapped demand for U.S. companies entering European markets. His work spans consumer products, luxury goods, medical devices, and industrial segments across Europe, Asia, and North America.
Ursuy's background blends commercial execution with academic rigor: early career roles in global business development and M&A support in Munich and Vienna, procurement transformation leadership in the U.S., and a decade building applied consulting programs that prepare teams to deliver executive-level international strategy.
Your innovation belongs on the world stage.
We provide the engine to get it there.